Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report,
WeiterlesenAutor: Firma Kuros Biosciences
Kuros Biosciences’s MagnetOs Granules cleared by FDA for expanded spinal indications
Rare clearance for bone graft for standalone use in spine based on human clinical data Clearance attained with evidence from Level 1 randomized controlled trial
WeiterlesenKuros Biosciences wins 2020 Spine Technology Award from Orthopedics This Week
. Industry-leading award recognizes Kuros’ Fibrin-PTH (KUR-113) technology Rounds off successful year of commercial, clinical, and financial progress Kuros also wins GHP Magazine’s 2020 International
Weiterlesen